Uncategorized
AKB-9778 improves underlying diabetic retinopathy in TIME-2 study
AKB-9778 alone or in combination with ranibizumab improved underlying diabetic retinopathy in eyes with and without diabetic macular edema in the TIME-2 phase 2a study, Aerpio Therapeutics announced in a press release. Patients in the TIME-2 study were administered 15 mg of AKB-9778 alone, 15 mg of AKB-9778 in combination with 0.3 mg of Lucentis (ranibizumab, Genentech) or 0.3 mg of ranibizumab alone.